Mirum Pharmaceuticals (MIRM) Cost of Revenue (2023 - 2026)

Mirum Pharmaceuticals has reported Cost of Revenue for 4 years, with the latest figure at $28.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 25.14% year-over-year to $28.8 million; the trailing twelve-month figure through Mar 2026 stood at $106.0 million (up 22.11% YoY), and the FY2025 full-year result was $100.2 million, up 22.78% from the prior year.
• Cost of Revenue for Q1 2026 stood at $28.8 million, up from $28.3 million in the prior quarter.
• The five-year high for Cost of Revenue was $28.8 million in Q1 2026, with the low at $5.0 million in Q1 2023.
• Average Cost of Revenue over 4 years is $19.8 million, with a median of $22.8 million recorded in 2024.
• Peak annual rise in Cost of Revenue reached 258.1% in 2024, while the deepest fall reached 8.95% in 2024.
• Tracing MIRM's Cost of Revenue over 4 years: stood at $25.0 million in 2023, then retreated by 8.95% to $22.8 million in 2024, then advanced by 24.07% to $28.3 million in 2025, then gained by 1.91% to $28.8 million in 2026.
• The last three Cost of Revenue figures came in at $28.8 million (Q1 2026), $28.3 million (Q4 2025), and $25.5 million (Q3 2025), per Business Quant data.

Peer Comparison